MedTrace Logo

Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA

NCT00782197 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2010-10-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of PRGF infiltrations in the treatment of knee osteoarthritis.

Conditions

  • Joint Disease

Interventions

DEVICE

PRGF Intraarticular injection

Three consecutive PRGF injections each one week apart.

DEVICE

Hyaluronic Acid Intraarticular injection

Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.

Sponsors & Collaborators

  • Biotechnology Institute IMASD

    lead INDUSTRY

Principal Investigators

  • Mikel Sanchez · UCA (Unidad de Cirugía Artroscópica Mikel Sanchez). USP Clínica la Esperanza. C/LA Esperanza 3, 01002 Vitoria (Alava)SPAIN.

  • Jaime Usabiaga · Hospital Donostia

  • Javier Albillos · Policlinica Gipuzkoa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00782197 on ClinicalTrials.gov